Conclusion of License Agreement and Capital Alliance for BNC-1021 for the Treatment of Idiopathic Pulmonary Fibrosis
Bonac Corporation (“Bonac”; HQ: Kurume City, Fukuoka; CEO: Hirotake Hayashi) and Toray Industries, Inc. (Headquarters: Chuo-ku, Tokyo; President: Akihiro Nikkaku) announced on December 25th, 2015 the signing of a license agreement for development for the treatment of idiopathic pulmonary fibrosis and have concluded a capital alliance with Toray Industries, Inc.
Please refer below for further information.
-Toray, BONAC Sign Licensing Agreement Regarding BNC-1021 Targeting Idiopathic Pulmonary Fibrosis and Capital Alliance- | Latest News | Toray Industries, Inc. | TORAY
Bonac will continue to promote research and development so that our nucleic acid technology will become a bridge to drug discovery.